Jamie joined UNITY because he believes medicines that impact
senescence biology can improve the quality of human life. Before joining
UNITY, Jamie served in several roles at Takeda Pharmaceuticals as
Executive Vice President, including as Head, Cardiovascular and
Metabolism Therapeutic Area, and as the Head of both the Therapeutic
Areas Group and Experimental/Translational Medicine. Prior to joining
Takeda, he served in a number of roles at Eli Lilly & Co., including
as the Vice President for Translational Medicine and Tailored
Therapeutics. Across these roles, Jamie has brought more than 70
programs from Discovery to Development, leading and supporting efforts
through all phases, including the launches of 8 commercial products.
Jamie is committed to translating cutting edge science into actual
medicines that positively impact people. Prior to joining UNITY, Jamie
practiced medicine in Endocrinology & Metabolism and ran a basic
science laboratory at the University of Michigan.
Jamie Dananberg
Chief Medical Officer at Unity Biotechnology.
Visit website: https://unitybiotechnology.com/team/jamie-dananberg/
See also: UNITY Biotechnology - Biotechnology company devoted to research of restoring human health
Details last updated 05-Jan-2020
Jamie Dananberg is also referenced in the following:
Forever Young?
Lara Lewington interviews scientists, commentators and a "professional rejuvenation athlete" (Bryan Johnson)
Longevity Leaders World Congress 2022
26-Feb-2022 to 27-Feb-2022
Event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX)
Jamie Dananberg News
UNITY Biotech's lead compound lags behind the Regeneron’s eye drug
Biospace - 27-May-2023
UBX1325 showed disappointing results in phase II macular degeneration trial - further analysis is required
Read more...UNITY Biotechnology expands trial of osteoarthritis senolytic
UNITY Biotechnology - 22-Jan-2019
Initial results must be promising to enrol more patients at highest dosage
Read more...UNITY Treats First Patient with UBX0101
UNITY Biotechnology - 25-Jun-2018
The company is going to test a new Senolytic drug in human trials
Read more...